Nobel Biocare Board of Directors nominates candidates for electi

Media release

ZURICH, SWITZERLAND - 18 FEBRUARY 2013

Nobel Biocare Board of Directors nominates candidates for election as members
of the Board at the Annual General Meeting 2013

Nobel Biocare announced today that Oskar K. Ronner has withdrawn his
shareholder proposal and informed the Board that he and his two proposed
candidates will not run for election to the Board of Directors of the Company.
The Board acknowledges this decision although it would have welcomed Mr.
Ronner joining the Board.

All current members of the Board of Directors will stand for re-election at
the Annual General Meeting on 28 March 2013. As already announced on 18
January 2013, Franz Maier will be proposed as a new member of the Board. The
invitation to the Annual General Meeting and the complete agenda will be
published in late February.

After the General Meeting, the Board of Directors will constitute itself and
will elect Dr. Rolf Watter as Chairman of the Board of Directors. It will also
decide on the committees and their composition.

For further information, please contact:

Süha Demokan

VP Investor and Corporate Relations

Tel.: +41 43 211 42 30, +41 79 430 81 46

suha.demokan@nobelbiocare.com

Disclaimer

This media release contains forward-looking statements based on beliefs of
Nobel Biocare's management. When used in this media release, words such as
"anticipate", "believe", "estimate", "expect", "intend", "plan" and "project"
are intended to identify forward-looking statements. They may involve risks
and uncertainties, including technological advances in the medical field,
product demand and market acceptance, the effect of economic conditions, the
impact of competitive products and pricing, foreign currency exchange rates
and other risks. These forward-looking statements reflect the views of Nobel
Biocare as of the date made with respect to future events and are subject to
risks and uncertainties. All of these forward-looking statements are based on
estimates and assumptions made by management of the company and are believed
to be reasonable, though are inherently uncertain and difficult to predict.
Actual results or experience could differ materially from the forward-looking
statements. Nobel Biocare disclaims any intention or obligation to update
these forward-looking statements.

Nobel Biocare (NOBN, SIX Swiss Exchange) is a world leader in innovative
restorative and esthetic dental solutions. As a complete solutions provider,
Nobel Biocare offers the most comprehensive range of solutions from tooth to
root, for single tooth to fully edentulous indications. The solutions
portfolio covers dental implants (including the key brands NobelActive®,
Brånemark System® and NobelReplace®, individualized prosthetics and equipment
(NobelProcera® guided surgery solutions and biomaterials). Nobel Biocare has
approximately 2'500 employees and recorded revenue of EUR 569.2 million in
2011. The company is headquartered in Zurich, Switzerland. Production takes
place at seven sites located in Canada, Israel, Japan, Sweden, and the US.
Nobel Biocare has 34 direct sales organizations.

Media release (PDF)

Provider                  Channel         Contact
Tensid Ltd., Switzerland  newsbox.ch      Provider/Channel related enquiries
www.tensid.ch             www.newsbox.ch  marco@tensid.ch
                                          +41 41 763 00 50